THE WHAT? Kimberly-Clark has reported a 30 percent increase in Rogaine sales this year, with growing adoption of GLP-1 weight-loss medications potentially contributing to increased demand for hair loss treatments.
THE DETAILS Kimberly-Clark CEO Mike Hsu highlighted the growth during an analyst call, suggesting that rising use of GLP-1 medications could be supporting demand for Rogaine, which joined the company’s portfolio through its acquisition of Kenvue. Rapid weight loss has been associated with temporary hair shedding, creating additional demand for targeted hair care treatments, although a direct link between GLP-1 medications and Rogaine’s sales growth has not been established. Rogaine holds approximately 9 percent of the global hair loss prevention market,valued at around valued at around US$10 billion in 2025 and projected to reach US$ 23 billion by 2035,, according to Future Market Insights.
THE WHY? Rogaine’s performance highlights growing commercial demand for targeted hair loss treatments as changing consumer health and lifestyle trends influence the global hair care market. The sales increase demonstrates the potential for established treatment brands to benefit from emerging consumer needs without relying on new product launches.
Source: Bloomberg
